Published in Infect Immun on April 01, 1983
Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev (2000) 4.59
A minor high-molecular-weight outer membrane protein of Haemophilus influenzae type b is a protective antigen. Infect Immun (1985) 2.81
Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun (1991) 2.32
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun (1991) 2.11
Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun (1986) 1.79
Protection of infant rats from Haemophilus influenzae type b infection by antiserum to purified outer membrane protein a. Infect Immun (1987) 1.75
Important science--it's all about the SPIN. Infect Immun (2009) 1.59
Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med (1987) 1.56
Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun (1991) 1.44
Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun (1990) 1.43
Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun (1991) 1.42
Haemophilus influenzae type b conjugate vaccines. Immunology (2004) 1.37
Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun (1984) 1.34
Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect Immun (1995) 1.32
Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect Immun (1986) 1.30
Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197. J Clin Invest (1985) 1.25
Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun (1992) 1.23
Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect Immun (1993) 1.21
Cloning and surface expression in Escherichia coli of a structural gene encoding a surface protein of Haemophilus influenzae type b. Infect Immun (1985) 1.21
Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates. Infect Immun (1988) 1.12
Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis. Infect Immun (1984) 1.12
Serum opsonic activity after immunization of adults with Haemophilus influenzae type b-diphtheria toxoid conjugate vaccine. Infect Immun (1985) 1.09
Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex. Infect Immun (1992) 1.00
Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun (2001) 1.00
Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice. Infect Immun (1983) 0.98
Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect Immun (1997) 0.95
Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin. Infect Immun (1992) 0.95
Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infect Immun (1993) 0.95
Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine (2010) 0.94
Immunogenicity of Vibrio vulnificus capsular polysaccharides and polysaccharide-protein conjugates. Infect Immun (1993) 0.92
Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol (2009) 0.89
Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes. Infect Immun (1995) 0.89
Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b. Infect Immun (2004) 0.87
Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae. Infect Immun (1999) 0.85
Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice. Infect Immun (2003) 0.82
Conjugation of yeast mannans with protein employing cyanopyridinium agent (CDAP)--an effective route of antifungal vaccine preparation. Glycoconj J (2000) 0.82
Population subdivision and the detection of recombination in non-typable Haemophilus influenzae. Microbiology (2012) 0.82
Qualitative and quantitative analyses of the antibody response elicited by Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in adults with IgG subclass deficiencies and frequent infections. Clin Exp Immunol (1994) 0.80
Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front Immunol (2014) 0.79
Identification of B- and T-cell epitopes of BB, a carrier protein derived from the G protein of Streptococcus strain G148. Clin Diagn Lab Immunol (2003) 0.76
Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer. Hum Vaccin Immunother (2014) 0.75
Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization. Infect Immun (2001) 0.75
Use of immuno assays during the development of a Hemophilus influenzae type b vaccine for technology transfer to emerging vaccine manufacturers. Hum Vaccin Immunother (2014) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol (1972) 40.51
CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : I. THE SYNTHESIS OFp-AMINOPHENOL beta-GLUCOSIDE, p-AMINOPHENOL beta-GALACTOSIDE, AND THEIR COUPLING WITH SERUM GLOBULIN. J Exp Med (1929) 12.63
VARIATION AND TYPE SPECIFICITY IN THE BACTERIAL SPECIES HEMOPHILUS INFLUENZAE. J Exp Med (1931) 7.52
Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med (1980) 5.32
A method for the quantitative modification and estimation of carboxylic acid groups in proteins. J Biol Chem (1967) 4.65
Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics (1977) 4.64
A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol Metab (1971) 4.38
Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res (1973) 3.89
Effect of combinations of inbred strain, antigen, and antigen dose on immune responsiveness and reagin production in the mouse. A potential mouse model for immune aspects of human atopic allergy. Int Arch Allergy Appl Immunol (1970) 3.55
Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b. Pediatrics (1973) 3.33
Antibody response of infants to cell surface-exposed outer membrane proteins of Haemophilus influenzae type b after systemic Haemophilus disease. Infect Immun (1982) 3.18
The derivatization of cross-linked polyacrylamide beads. Controlled introduction of functional groups for the preparation of special-purpose, biochemical adsorbents. Biochemistry (1969) 2.89
Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med (1980) 2.85
Immunization of humans with polyribophosphate, the capsular antigen of Hemophilus influenzae, type b. J Clin Invest (1972) 2.81
A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol Methods (1980) 2.65
Capsular polymer of Haemophilus influenzae, type b. I. Structural characterization of the capsular polymer of strain Eagan. J Biol Chem (1975) 2.30
Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med (1978) 2.18
Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med (1975) 2.16
Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand (1977) 2.11
Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease. N Engl J Med (1978) 1.86
Human antibody response to individual outer membrane proteins of Haemophilus influenzae type b. Infect Immun (1982) 1.83
Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis (1981) 1.71
THE ACTION OF TYPE-SPECIFIC HEMOPHILUS INFLUENZAE ANTISERUM. J Exp Med (1933) 1.62
Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides. Infect Immun (1979) 1.61
Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect Immun (1982) 1.56
Immunization against neonatal tetanus in New Guinea. 3. The toxin-neutralization test and the response of guinea-pigs to the toxoids as used in the immunization schedules in New Guinea. Bull World Health Organ (1970) 1.52
Inhibitory effect of K-76 monocarboxylic acid, an anticomplementary agent, on the C3b inactivator system. J Immunol (1981) 1.50
Structural studies of the capsular antigen from Streptococcus pneumoniae type 26. Carbohydr Res (1979) 1.48
The bacteriology of pneumococcal otitis media. Johns Hopkins Med J (1977) 1.36
The modulating effect of cholera enterotoxin on the immune response. J Immunol (1974) 1.26
Accelerated and prolongated multiplication of antibody-forming spleen cells by Bordetella pertussis in mice immunized with sheep red blood cells. Experientia (1967) 1.20
Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev Infect Dis (1981) 1.15
Age-related response to two Haemophilus influenzae type b vaccines. J Pediatr (1982) 1.14
Safety and immunogenicity of a new Haemophilus influenzae type b vaccine in infants under one year of age. Lancet (1981) 1.10
The effect of Bordetella pertussis on the antibody response in mice to type III pneumococcal polysaccharide. J Immunol (1976) 1.09
Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg county, North Carolina (March 1974-March 1976). J Infect Dis (1977) 1.08
The Protective or Curative Element in Type B H. influenzae Rabbit Serum. Yale J Biol Med (1944) 1.04
Subunit association and heterogeneity of Limulus polyphemus hemocyanin. Biochemistry (1978) 1.03
Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B. J Immunol (1982) 0.99
Formation of IgE-binding factors by rat T lymphocytes. II. Mechanisms of selective formation of IgE-potentiating factors by treatment with Bordetella pertussis vaccine. J Immunol (1981) 0.97
A study of the pneumococcal vaccine in prevention of clinically acute atttacks of recurrent otitis media. Rev Infect Dis (1981) 0.96
Modification of antibody response to type III pneumopolysaccharide by route of injection of pertussis vaccine. Infect Immun (1979) 0.91
Haemophilus influenzae type B polysaccharide-protein conjugates: model for a new generation of capsular polysaccharide vaccines. Prog Clin Biol Res (1980) 0.84
Antibody responses to a combination vaccine against Haemophilus influenzae type b, diphtheria, pertussis, and tetanus. Bull World Health Organ (1975) 0.83
Semi-synthetic vaccines composed of capsular polysaccharides of pathogenic bacteria covalently bound to proteins for the prevention of invasive diseases. Prog Allergy (1983) 0.80
Immunoglobulin E-suppressing and immunoglobulin G-enhancing tetanus toxoid prepared by conjugation with pullulan. Infect Immun (1982) 0.80
Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med (1974) 7.89
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science (2001) 6.29
Epidemiology of Escherichia coli K1 in healthy and diseased newborns. Lancet (1975) 6.25
Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature (1996) 6.17
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med (1980) 5.32
Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol (1985) 4.88
A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol Metab (1971) 4.38
A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet (1996) 4.30
Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis (1984) 4.10
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med (2001) 4.08
Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res (1973) 3.89
"Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet (1997) 3.68
Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis (1995) 3.25
Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem (1996) 3.05
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol (1985) 2.97
Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem (1996) 2.95
Lipid on capsular polysaccharides of gram-negative bacteria. J Biol Chem (1981) 2.91
Frequency of E. coli K antigens in urinary-tract infections in children. Lancet (1977) 2.89
Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J Exp Med (1979) 2.89
Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b. Lancet (1971) 2.84
Use of antiserum agar for detection of Haemophilus influenzae type b in the pharynx. Pediatr Res (1975) 2.74
Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis (1990) 2.72
Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet (1974) 2.67
Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry (1978) 2.65
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet (1987) 2.59
Comparative analysis of plasmids and some metabolic characteristics of Escherichia coli K1 from diseased and healthy individuals. Infect Immun (1980) 2.59
The isolation and biologic activities of purified secretory IgA and IgG anti-Salmonella typhimurium "O" antibodies from rabbit intestinal fluid and colostrum. J Immunol (1971) 2.54
Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun (1972) 2.47
Serogroup identification of Neisseria meningitidis: comparison of an antiserum agar method with bacterial slide agglutination. J Clin Microbiol (1978) 2.44
Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett (1998) 2.40
Pathogenesis of neonatal Escherichia coli meningitis: induction of bacteremia and meningitis in infant rats fed E. coli K1. Infect Immun (1977) 2.39
Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun (1988) 2.36
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis (1977) 2.29
The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg (2000) 2.29
Differential complement resistance mediates virulence of Haemophilus influenzae type b. Infect Immun (1982) 2.23
Production of monovalent antisera by induction of immunological tolerance for capsular typing of Streptococcus pneumoniae. FEMS Microbiol Lett (1992) 2.19
Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis (1984) 2.17
Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med (1975) 2.16
Gamma-A-immunoglobulin from rabbit colostrum. J Immunol (1966) 2.16
Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet (1994) 2.15
Molecular cloning of the K1 capsular polysaccharide genes of E. coli. Nature (1981) 2.15
Emergency caesarean section in a patient with myotonic dystrophy: a case of failed postoperative extubation in a patient with mild disease. Anaesth Intensive Care (2011) 2.14
Clinical, bacteriological, and immunological characterisation of ampicillin-resistant Haemophilus influenzae type B. Lancet (1974) 2.14
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand (1977) 2.11
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun (1991) 2.11
Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis (2000) 2.04
The Vaccine Adverse Event Reporting System (VAERS). Vaccine (1994) 2.02
A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli. Pediatr Res (1976) 1.96
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 1.94
Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol Cell Biol (1994) 1.88
Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis (1977) 1.84
Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun (1986) 1.79
A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med (1995) 1.78
Photosynthetic and photorespiratory characteristics of flaveria species. Plant Physiol (1991) 1.78
Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. J Ind Microbiol Biotechnol (2002) 1.75
Use of antiserum agar plates for serogrouping of meningococci. J Clin Pathol (1977) 1.74
Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care (2008) 1.73
Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (1996) 1.71
Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun (1993) 1.70
Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun (1990) 1.69
PRoNTo: pattern recognition for neuroimaging toolbox. Neuroinformatics (2013) 1.64
Plant thioredoxin h: an animal-like thioredoxin occurring in multiple cell compartments. Arch Biochem Biophys (1991) 1.62
Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides. Infect Immun (1979) 1.61
Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine (1996) 1.59
Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med (1987) 1.56
Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis (1992) 1.53
Prospects for the prevention of bacterial meningitis with polysaccharide vaccines. Bull World Health Organ (1978) 1.52
Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply. Vaccine (1998) 1.51